Identification of GDP as a small inhibitory molecule in HepG2 cells by nontargeted metabolomics analysis

Zhilin Peng1,2, Siting Xu1,2, Haocheng Wang1,2

  • 1The Center for Heart Development, College of Life Science, Hunan Normal University, Changsha, Hunan 410081, P.R. China.

Oncology Letters
|February 24, 2025
PubMed

Insights

Fatty acid hydroxylase domain containing 2 (FAXDC2) influences liver cancer by altering guanosine diphosphate (GDP) levels. Increased GDP inhibits cancer cell viability, proliferation, and invasion, offering new therapeutic targets for liver cancer.

Area of Science:

  • Biochemistry
  • Oncology
  • Metabolomics

Background:

  • Lipid metabolism dysregulation is implicated in cancer development.
  • Fatty acid hydroxylase domain containing 2 (FAXDC2) is downregulated in cancer and affects liver cancer cell proliferation and migration via ERK signaling.
  • The precise metabolic mechanisms linking FAXDC2 to liver cancer progression remain unclear.

Purpose of the Study:

  • To elucidate the functional mechanism of FAXDC2 in liver cancer through metabolic profiling.
  • To investigate the role of altered metabolites in FAXDC2-mediated inhibition of liver cancer cells.
  • To explore potential therapeutic strategies targeting lipid metabolism in liver cancer.

Main Methods:

  • Overexpression of FAXDC2 in HepG2 liver cancer cells.
  • Metabolomics analysis to identify altered metabolites.
  • AlphaFold3 prediction for protein-metabolite interaction.
  • Cell Counting Kit-8, western blotting, and Transwell assays to assess cell viability, proliferation, invasion, and signaling pathways.

Main Results:

  • Guano sine diphosphate (GDP) was identified as a significantly altered metabolite upon FAXDC2 overexpression.
  • AlphaFold3 predicted a robust interaction between FAXDC2 and GDP.
  • Elevated GDP concentrations reduced HepG2 cell viability, proliferation (downregulating cyclin-dependent kinase 4 and cyclin D1), and invasion.
  • GDP treatment inhibited ERK signaling.

Conclusions:

  • This study identifies GDP as a novel, inhibitory small molecule metabolite in cancer, previously overlooked in tumor metabolic reprogramming.
  • GDP mediates the inhibitory effects of FAXDC2 on liver cancer cells by modulating cell function and ERK signaling.
  • Findings provide new insights and potential therapeutic strategies for liver cancer and other cancers through targeting metabolic pathways.

Related Concept Videos